To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Amylyx Pharmaceuticals sets IPO pricing terms
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, a developer of treatments for amyotrophic lateral sclerosis and other neurodegenerative diseases, has priced its IPO of 8.75 million shares at a price range between $18 and $20 per share.
